Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.0K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of a Meds-to-Beds Program to Reduce Readmissions After Percutaneous Coronary Intervention.

JACC. Advances·2026
Same author

The Need for Competency-Based Education.

American journal of pharmaceutical education·2024
Same author

Recommendations and Next Steps For Competency-Based Pharmacy Education.

American journal of pharmaceutical education·2023
Same author

Teplizumab Therapy to Delay the Onset of Type 1 Diabetes.

Cardiology in review·2023
Same author

Role of Influenza Vaccination in Cardiovascular Disease: Systematic Review and Meta-Analysis.

Cardiology in review·2023
Same author

Genetic Problems, Diagnosis, and Cardiovascular Manifestations of Loeys-Dietz Syndrome.

Cardiology in review·2023
Same journal

Immunometabolism in Cardiovascular Disease: Linking Metabolic Reprogramming to Inflammation, Atherothrombosis, and Clinical Outcomes.

Cardiology in review·2026
Same journal

Cardiotoxicity of Antibody-Drug Conjugates in HER2-Positive Cancer: Beyond Left Ventricular Ejection Fraction Decline.

Cardiology in review·2026
Same journal

Celiac Disease and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Challenges.

Cardiology in review·2026
Same journal

Valve-Specific Comparative Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists After Surgical Valve Procedures in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
Same journal

Growing Heart Valves in Congenital Cardiac Surgery: Mechanisms and Considerations for Tissue-Engineered Heart Valves, Noncryopreserved Homografts, and Partial Heart Transplantation.

Cardiology in review·2026
Same journal

Implementation Gaps and Limitations of Statin Therapy in Young Adults: Bridging Guideline Recommendations and Real-World Practice.

Cardiology in review·2026
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.1K

Celiprolol: A Unique Selective Adrenoceptor Modulator.

James J Nawarskas1, Angela Cheng-Lai, William H Frishman

  • 1From the *College of Pharmacy, University of New Mexico, Albuquerque, NM; †Department of Clinical Pharmacy, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; and ‡Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Cardiology in Review
|July 26, 2017
PubMed
Summary
This summary is machine-generated.

Celiprolol, a selective adrenoreceptor modulator, significantly reduced arterial events in vascular Ehlers-Danlos syndrome patients. This unique beta-blocker shows promise for treating this rare connective tissue disorder.

More Related Videos

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.4K
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.8K

Related Experiment Videos

Last Updated: Feb 25, 2026

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.1K
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.4K
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.8K

Area of Science:

  • Pharmacology
  • Cardiology
  • Genetics

Background:

  • Celiprolol is a beta-blocker with unique selective adrenoreceptor modulator properties.
  • It possesses antihypertensive and antianginal effects, approved for these uses globally.
  • In the US, its proposed indication is for vascular Ehlers-Danlos syndrome (vEDS).

Purpose of the Study:

  • To evaluate the efficacy of celiprolol in patients with vascular Ehlers-Danlos syndrome.
  • To assess celiprolol's potential to reduce vascular complications in vEDS.
  • To explore the therapeutic benefits of selective adrenoreceptor modulation in rare connective tissue disorders.

Main Methods:

  • A large-scale investigation of celiprolol in vEDS patients.
  • Clinical trial design focused on reducing arterial events.
  • Premature termination of the study due to observed significant benefit.

Main Results:

  • Celiprolol demonstrated significant benefit in reducing arterial events in vEDS patients.
  • The study was stopped early due to overwhelming positive outcomes.
  • Celiprolol effectively reduced mechanical stress on arterial walls by lowering heart rate and pulsatile pressure.

Conclusions:

  • Celiprolol shows significant therapeutic potential for vascular Ehlers-Danlos syndrome.
  • Its unique pharmacological profile distinguishes it from other beta-blockers.
  • Celiprolol represents a novel treatment option for life-threatening vascular complications in vEDS.